Ignyta prices IPO at $9.15

By
A A A

Ignyta, a clinical-stage biotech developing targeted cancer therapeutics, raised $48 million by offering 5.2 million shares at $9.15. The deal size was 20% greater than expected. Ignyta, which has traded with very low volume on the OTCQB and OTCBB since December 2013, will list on the NASDAQ under the symbol RXDX. Leerink Partners was the sole bookrunner on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: RXDX

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

24,872,990
  • $102.41 ▲ 0.27%
23,612,452
  • $16.045 ▼ 0.96%
17,043,022
  • $49.77 ▲ 3.56%
16,710,945
  • $13.10 ▼ 4.24%
10,872,161
  • $19.1032 ▼ 0.56%
10,742,083
  • $3.605 ▲ 0.42%
10,000,400
  • $10.89 ▼ 2.77%
9,456,737
  • $74.11 ▼ 0.70%
As of 8/28/2014, 11:07 AM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com